Amunix grabs $73M from Frazier, Omega to fuel shift to T cell engagers
A little over a year ago, Angie You was running commercial for a mid-sized Canadian biotech when she got an email from an investment firm with an offbeat proposal.
Frazier Health Partners was giving seed money to a 15-year-old company called Amunix. The biotech had long supplied half-life extension technology to big-name drugmakers, and now, after the death of one of the founders, Frazier was trying to turn it around entirely into a biotech that would make its own drugs. The change required not only a shift in technology, but also a significant shift in strategy. To that point, the company hadn’t taken a single investment dollar.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.